Obesity, Type 2 Diabetes
Conditions
Keywords
Obesity, Metformin, Physical activity, Cardiovascular health
Brief summary
The purpose of this study is to assess the sustainability of a two-year intervention aimed at improving body mass index (BMI) and metabolic and vascular health in obese youth. The study will compare lifestyle changes with diet and exercise alone with changes in lifestyle in combination with metformin medication. An initial intensive exercise program will also be compared with a standard exercise program. Hypothesis: Metformin therapy in combination with intensive lifestyle intervention in obese children and adolescents will be associated with reduced rate of weight gain, improved BMI, body composition, physical activity, physical fitness, insulin sensitivity, blood lipid profiles, adipocytokines and vascular function.
Detailed description
This study will assess the sustainability of a two-year intervention and the degree of improvement in body mass index (BMI) and reduction in risk factors for type 2 diabetes and diabetes related cardiovascular disease, as well as evaluating the additive effect of metformin (as GlumetzaTM 500 mg Extended Release Tablets) and comparing an initial intensive exercise program with a standard exercise program. The study will recruit obese youth who are at risk for type 2 diabetes and cardiovascular disease.
Interventions
DRUGMetformin and standard exercise
Metformin 1500 mg daily for 2 years
DRUGMetformin Intensive exercise
Metformin 1500 mg daily for 2 years
BEHAVIORALPlacebo Standard exercise
Standard exercise
BEHAVIORALIntensive exercise
Placebo Intensive exercise
Sponsors
Canadian Institutes of Health Research (CIHR)
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
10 Years to 16 Years
Healthy volunteers
Yes
Inclusion criteria
* Obese adolescents defined as BMI greater than the 95th percentile for age and gender * Metformin naive subjects
Exclusion criteria
* Elevated fasting plasma glucose ≥ 6.0 mmol/L * 2 hour plasma glucose ≥ 11.1 mmol/L after a standard glucose load * A1C \> 6.0% * Medication other than over the counter drugs, oral contraceptive pill or thyroid hormone replacement * Smoking * Pregnancy * Renal insufficiency (serum creatinine \> the upper limit of normal) * Hepatic dysfunction (\> 1.5 times the upper limit of normal for AST and ALT) * Latex Allergy * Hypersensitivity to metformin or its ingredients * Breast feeding * Subjects with a history of lactic acidosis * Abnormal creatinine clearance * HIV, HBV, and HCV infections * Drug and alcohol abuse * Severe mental disorders * Subjects who are planning radiologic exams involving in i.v. injection of iodinated contract materials * Participation in another clinical trial * Significant history or presence of cardiovascular, pulmonary, gastrointestinal, immunologic, endocrine, neurologic disorders * Malignant diseases * Previous exposure to any pharmaceutical antidiabetic agent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in BMI | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in physical activity | 2 years |
Countries
Canada
Outcome results
None listed